WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205521

CAS#: 910634-41-2

Description: Litronesib, also known as LY2523355, is a n inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. The ATP-dependent Eg5 kinesin-related motor protein (also known as KIF11 or kinesin spindle protein-5) is a plus-end directed kinesin motor protein that plays an essential role during mitosis, particularly in the regulation of spindle dynamics, including assembly and maintenance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Chemical Structure

CAS# 910634-41-2

Theoretical Analysis

MedKoo Cat#: 205521
Name: Litronesib
CAS#: 910634-41-2
Chemical Formula: C23H37N5O4S2
Exact Mass: 511.23
Molecular Weight: 511.701
Elemental Analysis: C, 53.99; H, 7.29; N, 13.69; O, 12.51; S, 12.53

Price and Availability

Size Price Availability Quantity
10mg USD -2
25mg USD -2
50mg USD -2
100mg USD -2
200mg USD -2
500mg USD -2
1g USD -1
2g USD -1
5g USD -1
Bulk inquiry

Synonym: litronesib; Eg5 KinesinRelated Motor Protein Inhibitor LY2523355; Code name: LY2523355; KF 89617.

IUPAC/Chemical Name: (R)-N-(5-((2-(ethylamino)ethylsulfonamido)methyl)-5-phenyl-4-pivaloyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)pivalamide.


InChi Code: InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1

SMILES Code: CC(C)(C)C(NC1=NN(C(C(C)(C)C)=O)[C@@](C2=CC=CC=C2)(CNS(=O)(CCNCC)=O)S1)=O

Appearance: Solid powder

Purity: >98%

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 511.700980000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Detection of circulating mRNA, microRNA, protein and vesicle markers in disease diagnosis and selection of therapies By Kuslich, Christine; Poste, George; Klass, Michael; Spetzler, David; Pawlowski, Traci From PCT Int. Appl. (2011), WO 2011127219 A1 20111013. 2. Stable lyophilized and injectable formulations of thiadiazole derivative By Kusano, Hiroko; Mishra, Dinesh Shyamdeo; Tashiro, Yoshikazu; Watanabe, Yosuke; Zhuang, Hong From PCT Int. Appl. (2009), WO 2009009470 A1 20090115. 3. Preparation of thiadiazoline derivatives as therapeutic agents for restenosis By Nakai, Ryuichiro; Shimoike, Emi; Kusaka, Hideaki; Murakata, Chikara; Yamashita, Yoshinori From PCT Int. Appl. (2006), WO 2006137490 A1 20061228. 4. antiglaucoma agents containing thiadiazoline derivatives By Miki, Ichiro; Nakai, Ryuichiro; Murakata, Isamu; Yamashita, Nobunori; Oshima, Etsuo From Jpn. Kokai Tokkyo Koho (2006), JP 2006265107 A 20061005. 5. Preparation of thiadiazole derivatives for treatment of arthritis By Miki, Ichiro; Uchii, Masako; Murakata, Chikara; Yamashita, Yoshinori; Suda, Toshio From PCT Int. Appl. (2006), WO 2006101104 A1 20060928. 6. Preparation of thiadiazoline compounds for the treatment of solid tumor By Murakata, Chikara; Kato, Kazuhiko; Yamamoto, Junichiro; Nakai, Ryuichiro; Okamoto, Seiho; Ino, Yoji; Kitamura, Yushi; Saitoh, Toshikazu; Katsuhira, Takeshi From PCT Int. Appl. (2006), WO 2006101102 A1 20060928. 7. Thiadiazoline derivatives for the treatment of psoriasis By Miki, Ichiro; Uchii, Masako; Kobayashi, Katsuya; Harada, Daisuke From PCT Int. Appl. (2006), WO 2006101105 A1 20060928. 8. Preparation of thiadiazoline derivatives for the treatment of hematopoietic tumor By Nakai, Ryuichiro; Okamoto, Seiho; Kusaka, Hideaki; Yamashita, Yoshinori; Ishida, Hiroyuki From PCT Int. Appl. (2006), WO 2006101103 A1 20060928.